In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
AstraZeneca, Sinopharm and Moderna were part of the study
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
